10-K: PetMed Express Reports Significant Sales Decline and Net Loss

PetMed Express, Inc. announced its annual report for the fiscal year ended March 31, 2026, detailing a substantial decrease in net sales and a significant increase in net loss, alongside ongoing efforts to remediate material weaknesses in internal controls.

Summary

• PetMed Express, Inc. reported a net loss of $57.3 million for the fiscal year ended March 31, 2026, a significant increase from a $6.3 million loss in the prior year.
• Net sales decreased by 21.1% to $179.0 million, primarily driven by a decline in prescription medication sales.
• The company experienced a goodwill and intangible asset impairment charge of $27.3 million.
• General and administrative expenses increased by 31.3% to $50.7 million, largely due to higher stock-based compensation and professional fees related to an investigation.
• The company has identified material weaknesses in internal controls related to sales taxes and IT general controls, although it has remediated weaknesses in income taxes, complex accounting matters, and tone at the top.
• The company's liquidity position has been impacted by declining cash balances and operating losses, raising substantial doubt about its ability to continue as a going concern, though management believes its plan alleviates this doubt.
• The company suspended its quarterly dividend indefinitely in February 2024 to focus cash flow on growth initiatives.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the significant decline in sales, widening net loss, substantial impairment charges, and ongoing material weaknesses in internal controls, indicating considerable financial and operational challenges.

Positives

• The company's AutoShip & Save subscription program showed continued adoption, with recurring sales representing 62.6% of total gross sales in the most recent quarter.
• Management believes its plan to optimize advertising spend, reduce operating expenses, and cut capital expenditures will alleviate concerns about the company's ability to continue as a going concern.
• The company passed all Department of Health inspections at its pharmacy locations.
• The company has a strong cybersecurity program aligned with industry standards.

Negatives

• Net sales decreased by 21.1% to $179.0 million for the fiscal year ended March 31, 2026.
• Net loss widened significantly to $57.3 million from $6.3 million in the prior fiscal year.
• Cost of sales as a percentage of sales increased to 71.9% from 69.5% due to an inventory write-down and lower sales.
• Gross profit margin decreased to 28.0% from 30.5%.
• General and administrative expenses increased by 31.3% to $50.7 million, impacting profitability.
• The company recorded a goodwill and intangible asset impairment charge of $27.3 million.
• Cash used in operating activities was $28.4 million for the fiscal year, compared to cash provided of $4.7 million in the prior year.
• Working capital decreased to $(8.4) million from $16.1 million.
• The company has identified material weaknesses in internal controls related to sales taxes and IT general controls that are not yet fully remediated.
• The company's stock price has significantly declined over the past five years.

Risks

• Failure to comply with state or federal regulations governing pet health businesses could lead to sanctions, fines, or loss of pharmacy licenses.
• Resistance from veterinarians to authorize prescriptions or attempts to discourage customers from using online pharmacies could decrease sales.
• Significant portions of sales are concentrated in eight states; losing pharmacy licenses in these states would materially affect financial results.
• Non-compliance with manufacturers' Minimum Advertised Pricing (MAPP) policies could result in forfeiture of rebates, suspension of purchases, or termination of business relationships.
• Disruptions to shipping arrangements or increased shipping costs could adversely affect the business.
• Failure to provide adequate customer service could lead to customer loss.
• Potential liability from website content, intellectual property infringement, or cybersecurity incidents.
• Inability to protect intellectual property rights or claims of infringing on others' rights.
• Business interruptions due to damage or disruptions at the company's two main facilities, particularly in hurricane-sensitive areas.
• Failure or misuse of information systems and customer-facing technology could adversely affect operations and expose the company to fraud.
• Cybersecurity incidents could damage reputation and harm financial condition.
• Migration of data and systems to new IT platforms may disrupt operations.
• Failure to effectively adopt emerging technologies like AI could put the company at a competitive disadvantage.
• Evolving privacy, data protection, marketing, and advertising laws and regulations could increase compliance costs and limit business practices.
• Litigation risks related to unauthorized text messages violating the Telephone Consumer Protection Act.
• Trade restrictions, tariffs, or customs limitations could increase costs or diminish product availability.
• Uncertainties in economic conditions and their impact on consumer spending patterns could adversely affect the business.
• Failure to manage acquisitions, investments, or strategic alliances effectively could have a material adverse effect.
• The pet telemedicine market is immature and uncertain, potentially affecting partnerships.
• Product recalls or concerns regarding the safety and quality of pet products could affect the business.
• Pandemics or other health crises could adversely affect results of operations.
• Stock price volatility could subject the company to litigation.
• The company has identified material weaknesses in internal control over financial reporting, which could adversely affect its business and share price.
• Taxing authorities may successfully assert that the company should have collected sales and use taxes, leading to substantial liabilities.

Future Outlook

The company's strategy focuses on transitioning to a best-in-class pharmacy provider through technology modernization, clinical compliance, and diversifying revenue streams by offering pharmacy fulfillment and licensing capabilities to strategic partners. They also plan to partner with veterinarians for integrated pharmacy fulfillment and develop a robust loyalty program to enhance customer retention and lifetime value. The company aims to leverage its 30 years of data to personalize customer experiences.

Management Comments

• Management believes that a high level of customer care and support has been and continues to be critical in retaining and expanding our customer base.
• We are redefining the customer journey by leveraging modern technology and Artificial Intelligence ('AI') to personalize the customer experience.
• Looking ahead, our strategy focuses on deepening customer trust and expanding our market footprint through three key pillars: loyalty and retention, strategic B2B partnerships, and improved content and education.
• We believe these purposeful investments in the foundation of our core business as a pharmacy will drive sustainable competitive advantages and long-term shareholder value.

Industry Context

StockSavvy.ai notes that the pet industry continues to grow, with total U.S. pet industry spend reaching approximately $158 billion in 2025, driven by food, treats, veterinary care, and supplies. The 'humanization' of pet healthcare is increasing demand for wellness products, presenting opportunities for companies like PetMed Express. However, the company faces significant competition from veterinarians, traditional retailers, and other online vendors, with several large retailers entering the pet pharmacy space.

Comparison to Industry Standards

• The company's gross profit margin of 28.0% is below the industry average for e-commerce retailers, which typically range from 35-50%.
• The increase in customer acquisition cost (CAC) to $81 is higher than industry benchmarks, which often aim for CAC below $50 for subscription-based models.
• The company's reliance on AutoShip, representing 62.6% of Q4 sales, aligns with industry trends favoring recurring revenue models, but the overall sales decline indicates challenges in customer retention or acquisition.
• The significant goodwill impairment charge suggests that the acquisition of PetCareRx did not yield the expected financial returns compared to industry norms for successful integrations.

Management Changes

Corporate Governance

Legal Proceedings

• Plaintiff Timothy Fitchett filed an action in Pennsylvania alleging violation of Unfair Trade Practices and Consumer Protection Law by misrepresenting regular prices for products.
• Plaintiffs Ashley Bird, Tyler Dvornski, and Tiffany Hughes filed an action in New York alleging misrepresentation of sale prices and artificial inflation of prices, violating New York and California consumer protection laws.

Related Party Transactions

• In fiscal 2024, the company entered into a master services agreement with Fabric, Inc., a company in which the former CEO was an equity holder and board member. Payments to Fabric were $105,000 in fiscal 2025. Fabric is no longer considered a related party after the former CEO's departure in August 2025.

Stakeholder Impact

• Shareholders: The significant net loss, goodwill impairment, and material weaknesses in internal controls negatively impact shareholder value and confidence. The suspension of dividends also affects income-seeking investors.
• Employees: The company's financial performance and ongoing control issues could create job insecurity. Management is focused on employee development and maintaining a strong corporate culture.
• Customers: The company emphasizes customer care and aims to provide convenient and affordable pet health solutions. However, potential disruptions from IT system modernizations or cybersecurity incidents could impact service.
• Suppliers: The company relies on key suppliers and maintains purchasing agreements. Any disruption in these relationships or supplier issues could impact inventory availability and costs.

Next Steps

• Continue to implement and evaluate remediation plans for material weaknesses in sales tax and IT general controls.
• Modernize technology infrastructure, including e-commerce architecture and cloud environments.
• Expand educational initiatives to drive customer adherence for critical preventative medications.
• Diversify revenue streams by offering proprietary pharmacy fulfillment and licensing capabilities to strategic partners.
• Partner with veterinarians and clinics to provide integrated pharmacy fulfillment services.
• Develop a robust loyalty and membership program to incentivize long-term retention and optimize customer lifetime value.
• Leverage 30 years of pet profile data to personalize customer experiences online and through mobile apps.
• Continue to optimize advertising and media spend and strategically reduce operating expenses.
• Continue to monitor and update regulatory licenses in every state and the U.S. Virgin Islands.

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, marked by a substantial increase in net loss, a sharp decline in sales, and a significant goodwill impairment. The ongoing material weaknesses in internal controls, particularly concerning sales taxes and IT general controls, coupled with the company's precarious liquidity position and the ongoing need for operational restructuring, present substantial risks. While the company has a strategy for future growth and has remediated some control issues, the current financial health and operational challenges suggest a high level of risk for investors. Therefore, a sell recommendation is warranted.

Keywords

PetMed Express, 10-K, Annual Report, Pet Pharmacy, Pet Medications, E-commerce, Financial Results, Net Sales, Net Loss, Goodwill Impairment, Internal Controls, Cybersecurity, Pet Health